Examining UCHL1 as a marker in acute heart failure
To Explore the Potential of UCH-L1 as a Novel Therapeutic and Diagnostic Target in Heart Failure
This study is trying to see if a protein called UCHL1 can help doctors understand how severe heart failure is in patients who are admitted to the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | VA Office of Research and Development Federal |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Columbia, South Carolina) |
| Trial ID | NCT04999995 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of UCHL1, a deubiquitinating enzyme, in the progression of acute decompensated heart failure (ADHF). It aims to understand how autophagy, a cellular degradation process, is linked to heart failure and whether UCHL1 can serve as a potential biomarker for disease progression. The study will enroll patients admitted for ADHF and assess their clinical data to explore the relationship between UCHL1 levels and heart failure severity. By analyzing these connections, the research seeks to enhance understanding of heart failure mechanisms and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are admitted for acute decompensated heart failure.
Not a fit: Patients with conditions such as acute stroke or decompensated liver disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools for monitoring and managing acute heart failure.
How similar studies have performed: While the specific approach of using UCHL1 as a biomarker in heart failure is novel, related studies on autophagy and heart failure have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Admission for decompensated HF (traditional diagnostic criteria will be utilized for diagnosing ADHF - presence of dyspnea as presenting complaint; evidence of volume overload - peripheral or pulmonary edema, elevated jugular venous pressure \> 10 cmH2O, presence of hepatojugular reflux, or ascites; elevated B-type Natriuretic Peptide (\>100ng/ml); evidence of pulmonary vascular congestion on chest x-ray1, or Admission for dyspnea that is NOT related to ADHF (absence of all HF symptoms and signs mentioned in ADHF inclusion criteria- except for dyspnea as presenting complaint) * Able to give informed consent * Age \>= 18 years Exclusion Criteria: * Mortality during inpatient observation * Presence of acute stroke (ischemic or hemorrhagic) * Presence of intracranial hemorrhage * History of acute stroke (ischemic or hemorrhagic) or intracranial hemorrhage within the preceding 6 months * Presence of decompensated liver disease (elevated ALT/AST; ascites; Acute variceal bleeding; or hepatic encephalopathy) * Presence of sepsis * Presence of severe hyponatremia (Serum sodium \< 130 meq/L) * Active malignancy (undergoing chemotherapy, radiation therapy, or planned surgical intervention) * SARS-CoV-2 positive during the current admission
Where this trial is running
Columbia, South Carolina
- Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC — Columbia, South Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Taixing Cui, PhD MB — Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC
- Study coordinator: Harshitha Kota, MD
- Email: harshitha.kota@va.gov
- Phone: (803) 776-4000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.